NTRC will present two scientific posters at the AACR Annual Meeting 2018, to be held from April 14th to 18th in Chicago. The first poster relates to Arginase, a promising target in the field of cancer immunotherapy. The poster describes a novel high-throughput assay technology that was used to screen for small molecule inhibitors of Arginase I. The screen was performed in collaboration with the Pivot Park Screening Centre.
The second poster relates to targeted therapies and drug response biomarkers. The poster presents the biochemical kinase assay and cell panel profiling data of all kinase inhibitors approved for clinical use. GeneNominator™ gene expression analysis revealed novel drug response biomarkers for BTK and CDK4/6 inhibitors, which will be presented in case studies.
Furthermore, representatives of NTRC will gladly welcome you at booth #1055 in the Exhibition Hall.
Details on the poster presentations are given below:
Title: High-throughput fluorescence-based assay for screening of Arginase I inhibitors for cancer immunotherapy
Presented by: Yvonne Grobben
Session Date and Time: Monday Apr 16, 2018 8:00 am – 12:00 pm
Poster Board Number: 19
Permanent Abstract Number: 1944
Title: Profiling of all clinically approved kinase inhibitors reveals novel drug response biomarkers for BTK and CDK4/6 inhibitors
Presented by: Joost Uitdehaag
Session Date and Time: Tuesday Apr 17, 2018 1:00 pm – 5:00 pm
Poster Board Number: 3
Permanent Abstract Number: 4907
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services, target residence time measurements, and immune oncology assays on a fee-for-service basis. For more information please visit www.ntrc.nl/services or contact email@example.com